Collectively, our data show that targeting the MTA1/mTOR pathway by the natural stilbene, gnetin C, is highly effective in a preclinical model of prostate cancer and suggests that it could be beneficial for blocking prostate cancer progression in a cohort of patients with a deregulated MTA1/PTEN/AKT/mTOR pathway (Figure 7). This evidence concerns the gene MTOR and prostate cancer.